FDA Psychedelic Hearing: Safety Testimony — Heart Risks, a 21-Year-Old's Death, Provider Misconduct — Sharpens the Framework Debate
At the FDA's September 14, 2026 public hearing on the potential future therapeutic use of psychedelics, the testimony that drew the most attention was about safety and who delivers care — not whether the drugs work. Follow-up coverage (Medical Daily, Sept 16) reports that speakers flagged cardiac risks, screening gaps, and provider misconduct, including "heart risks, screening gaps, and provider misconduct" raised alongside "a 21-year-old's death" cited in the hearing's aftermath.
The heart concern is grounded in the agency's own July 2026 final guidance on psychedelic clinical studies: it notes the serotonin 5-HT2B receptor "has been linked to heart valve disease in humans," recommends excluding people with existing valve disease or pulmonary hypertension from multiple-dose studies of such drugs "until the risk is better understood," and calls for heart ultrasounds before and after treatment if such drugs are given long term. The guidance also flags dangerous interactions (e.g., "Combining MAO inhibitors with MDMA or other amphetamine-based psychedelics can cause a life-threatening spike in blood pressure") and centers supervision: "The agency expects two trained monitors for the full session and warns that participants 'may remain in a vulnerable state for several hours or longer.'" If the lead monitor is not a physician, a licensed on-call physician should be able to reach the site within 15 minutes.
That 15-minute rule drew pushback: Jon Dalton, president of the Nevada Coalition for Psychedelic Medicines, warned it "could shut out qualified clinics in rural Nevada and other Western states." On qualifications, psychiatrist Rajan Dunne (Sheppard Pratt) called for required oversight by a psychiatrist, while nurse practitioner Tina Braddock argued nurses are "already trained and ready." Kevin Sabet (Foundation for Drug Policy Solutions) argued psychedelics should earn approval "through science and trials, not politics or podcasters," citing small Phase 3 samples, poor sampling, suppressed negative results, and sexual misconduct — an issue that "came up several times during the hearing." And Sagy warned "FDA approval will carry enormous cultural weight."
Process and what's next: written comments are open until 11:59 p.m. ET on October 5, 2026 on docket FDA-2026-N-7542. The FDA hasn't said when it will act; markers to watch are Compass's completed application and Definium's Q4 FDA meeting (Definium's DT120 LSD Phase 3 Panorama win — 245 patients, company-announced topline — remains unreviewed by the agency; see Definium's LSD-Derived DT120 ODT Delivers Third Straight Phase 3 Clinical Win in Generalized Anxiety Disorder).
What it means: the hearing is shifting the debate from efficacy to delivery-model design — screening, cardiac monitoring, monitor staffing, and rural access — which will shape whatever supervised-use framework FDA eventually proposes.